Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com
Patients and Caregivers

Personalized breast cancer care starts with genomic testing

Surgery. Radiation. Hormonal therapy. Chemotherapy. Some, or a combination. When it comes to breast cancer, there’s a whole arsenal of treatment options. But which one is right for you? Which treatment regimen is most appropriate for your particular tumor?

With the help of insights from the advanced genomics of the Oncotype DX® tests, you and your doctor can make informed treatment decisions based on your unique tumor.

Oncotype DX Breast Recurrence Score

Oncotype DX Breast Recurrence Score test

For patients with stages I-IIIA invasive breast cancer

For patients with stages I-IIIA invasive breast cancer, learn about the only genomic test proven to predict whether you are likely to benefit from chemotherapy. Plus, get an understanding of the testing process, learn what you can expect from the test results, watch patient stories, explore FAQs, and more.

Coree used the Breast Recurrence Score® results to help her choose the most appropriate treatment for her invasive breast cancer. Hear her story .

Tests are widely accessible, with minimal to $0 out-of-pocket costs for most patients*

At Exact Sciences, we’re working hard to ensure that you have access to what you need to make confident, informed decisions about your cancer treatment.

Learn about costs, coverage, and how Exact Sciences can help

 

*This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Patient cost-sharing amounts, including deductibles and copays, will vary by plan and coverage type. Only your patient’s insurer can confirm if and how the Oncotype DX test will be covered.